Want to see HK:3869 full AI Analyst Report?
3869 Stock Chart & Stats
HK$3.40
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$3.40
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.00 - HK$7.55
Previous CloseN/A
Volume1.40K
Average Volume (3M)660.00
Market Cap
HK$469.86M
Enterprise ValueHK$791.78M
Total Cash (Recent Filing)HK$805.00M
Total Debt (Recent Filing)HK$1.06B
Price to Earnings (P/E)3.0
Beta0.03
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.99
Shares Outstanding138,194,000
10 Day Avg. Volume1,420
30 Day Avg. Volume660
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)4.07
Price to Sales (P/S)1.39
P/FCF Ratio14.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue & Profit ReboundA material revenue re-acceleration (+35.3% in 2025) and return to ~9.3% net margin signal demand recovery and improved operational leverage. Sustained top-line growth with continued margin recovery would underpin durable cash generation, reinvestment capacity and financing flexibility.
Positive Free Cash Flow Track RecordConsistent positive free cash flow across the period shows the business can convert earnings into cash. Even with a 2025 decline, repeated FCF supports ongoing operations, debt service and capital spending without reliance on external equity, a durable financial strength if revenues hold.
Stronger ROE And Equity BaseA sharp ROE recovery (~27%) and an increased equity base improve capital efficiency and provide a larger loss-absorbing buffer. Improved shareholder equity and returns suggest management rebuilt profitability, bolstering long-term resilience and capacity to invest in growth initiatives.
Bears Say
High LeverageElevated leverage (debt-to-equity ~2.1x) leaves the company sensitive to interest costs and cyclical slowdowns. High gearing constrains strategic flexibility, increases refinancing risk, and makes cash flow variability more impactful on solvency over the medium term.
Limited Deleveraging CapacityModest operating cash flow versus a large debt stock and a 25.5% fall in FCF in 2025 reduce the firm's ability to pay down leverage quickly. Without sustained profit and cash growth, balance sheet repair will be slow, raising medium-term financing and rating vulnerability.
Earnings Volatility And Margin PressureProfitability has swung from a 2024 loss to a 2025 rebound, but margins are below 2023 peaks. This earnings volatility complicates forecasting and undermines reliable cash conversion, increasing the company's exposure to demand shifts and cost pressures over the next several quarters.
Hospital Corporation of China Ltd News
3869 FAQ
What was Hospital Corporation of China Ltd’s price range in the past 12 months?
Hospital Corporation of China Ltd lowest stock price was HK$1.00 and its highest was HK$7.55 in the past 12 months.
What is Hospital Corporation of China Ltd’s market cap?
Hospital Corporation of China Ltd’s market cap is HK$469.86M.
When is Hospital Corporation of China Ltd’s upcoming earnings report date?
Hospital Corporation of China Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 31 days.
How were Hospital Corporation of China Ltd’s earnings last quarter?
Hospital Corporation of China Ltd released its earnings results on Mar 26, 2026. The company reported -HK$0.139 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.139.
Is Hospital Corporation of China Ltd overvalued?
According to Wall Street analysts Hospital Corporation of China Ltd’s price is currently Overvalued.
Does Hospital Corporation of China Ltd pay dividends?
Hospital Corporation of China Ltd does not currently pay dividends.
What is Hospital Corporation of China Ltd’s EPS estimate?
Hospital Corporation of China Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hospital Corporation of China Ltd have?
Hospital Corporation of China Ltd has 138,194,000 shares outstanding.
What happened to Hospital Corporation of China Ltd’s price movement after its last earnings report?
Hospital Corporation of China Ltd reported an EPS of -HK$0.139 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Hospital Corporation of China Ltd?
Currently, no hedge funds are holding shares in HK:3869
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hospital Corporation of China Ltd
Hospital Corporation of China Limited, an investment holding enterprise, primarily focuses on the administration and direct management of hospitals across the People's Republic of China. The company extends specialized management and consulting services to institutions like Yangsi Hospital, Cixi Hospital, and Jinhua Hospital, alongside providing comprehensive general medical care. Additionally, the firm is active in the wholesale distribution of pharmaceutical products. Established in 2014, Hospital Corporation of China Limited maintains its corporate headquarters in Beijing, PRC, and functions as a subsidiary of Vanguard Glory Limited.
Technical Analysis
Honliv Healthcare Management Group Co Ltd
―
Guangdong Kanghua Healthcare Co., Ltd. Class H
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Concord Healthcare Group Co., Ltd. Class H
―